Key Details
Price
$16.98Annual Revenue
$2.38 MAnnual EPS
-$0.57Annual ROE
16.68%Beta
5.42Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
N/ARecent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with UPB included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Upstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Release of results from the phase 2 study, using verekitug for the treatment of patients with Chronic Rhinosinusitis with Nasal Polyps, expected to be released in the 2nd half of 2025. The global Chronic Rhinosinusitis market is expected to reach $3.5 billion by 2027.
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company will be added to the Russell 2000® index as part of the planned fourth quarter initial public offering (IPO) additions effective at the open of the U.S. equity markets on December 23, 2024.
FAQ
- What is the primary business of Upstream Bio?
- What is the ticker symbol for Upstream Bio?
- Does Upstream Bio pay dividends?
- What sector is Upstream Bio in?
- What industry is Upstream Bio in?
- What country is Upstream Bio based in?
- Is Upstream Bio in the S&P 500?
- Is Upstream Bio in the NASDAQ 100?
- Is Upstream Bio in the Dow Jones?
- When does Upstream Bio report earnings?